Acutus Medical (AFIB) AI Stock Analysis

117 Followers

Acutus Medical

(Other OTC:AFIB)

Select Model

Rating:39Underperform

Price Target:$0.00▼(-100.00% Downside)

Action:initiatedcoverage

Date:07/20/25

The stock scores poorly primarily due to critical financial risks, including negative equity and unsustainable losses. Secondary concerns include its penny stock status and unprofitable valuation, outweighing revenue growth improvements.

Positive Factors

Innovative Product OfferingAcutus Medical's focus on innovative cardiac mapping systems positions it well in the growing electrophysiology market, offering potential for long-term growth through advanced medical technology.

Negative Factors

Financial InstabilityPersistent financial instability with negative cash flows and high leverage poses significant risks to long-term viability, limiting the company's ability to invest in growth or weather downturns.

Acutus Medical (AFIB) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap: $2,991
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.0
Beta (1Y): 9.66
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 85
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Acutus Medical Business Overview & Revenue Model

Company Description

Acutus Medical, Inc. is a company dedicated to the treatment of cardiac arrhythmias, focusing on the design, manufacturing, and commercialization of specialized tools for catheter-based ablation procedures. These solutions are utilized to manage a sp...

How the Company Makes Money

Acutus Medical generates revenue primarily through the sale of its medical devices and systems used in electrophysiology procedures. The company’s revenue model includes direct sales of its AcQMap® systems and disposable catheters to hospitals and cl...

Acutus Medical Financial Statement Overview

Summary

Despite strong revenue growth and improved cash flow, negative equity and persistent net losses indicate severe financial risk and solvency concerns.

Income Statement

35Negative

Balance Sheet

10Very Negative

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.16M	20.16M	7.16M	3.03M	17.26M	8.46M
Gross Profit	1.00M	1.01M	-3.14M	-1.91M	-15.66M	-7.42M
EBITDA	2.25M	2.25M	-5.33M	35.20M	-105.12M	-92.55M
Net Income	-9.55M	-9.55M	-81.66M	-39.62M	-117.68M	-101.98M
Balance Sheet
Total Assets	28.65M	28.65M	53.96M	133.44M	169.79M	192.53M
Cash, Cash Equivalents and Short-Term Investments	14.02M	14.02M	22.40M	70.45M	100.77M	131.07M
Total Debt	35.76M	35.76M	38.48M	38.86M	45.40M	41.08M
Total Liabilities	40.24M	40.24M	54.84M	58.42M	64.07M	65.95M
Stockholders Equity	-11.59M	-11.59M	-879.00K	75.02M	105.73M	126.58M
Cash Flow
Free Cash Flow	-31.77M	-31.77M	-63.34M	-89.02M	-109.66M	-96.39M
Operating Cash Flow	-31.66M	-31.66M	-63.12M	-85.03M	-99.68M	-85.17M
Investing Cash Flow	22.15M	22.15M	58.55M	104.75M	19.07M	-63.82M
Financing Cash Flow	-2.89M	-2.89M	-2.66M	-12.12M	79.57M	164.43M

Acutus Medical Risk Analysis

Acutus Medical disclosed 63 risk factors in its most recent earnings report. Acutus Medical reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.If our common stock is delisted from Nasdaq and is traded over-the-counter, your ability to trade and the market price of our shares of common stock may be negatively impacted.Q4, 2023

2.We historically had net losses, and our new business following the Restructuring may not be profitable or continue to generate any revenue.Q4, 2023

3.Our ability to continue to have the liquidity necessary to service our debt, meet contractual payment obligations and fund our operations depends on many factors, including our ability to generate sufficient cash flow from operations or obtain other financing.Q4, 2023

Acutus Medical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

AFIB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCEL	60Neutral	$491.10M	-13.13	146.38%	―	16.96%	34.83%
COCH	53Neutral	$52.13M	-1.80	-9999.00%	―	11.06%	64.70%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PAVM	47Neutral	$13.03M	-0.10	-54.72%	―	410.34%	-185.92%
CLPT	42Neutral	$271.82M	-7.01	-170.24%	―	32.51%	-46.56%
ECOR	42Neutral	$48.44M	-3.67	498.83%	―	27.26%	20.47%
AFIB	39Underperform	$2,991	0.00	153.11%	―	―	―

* Healthcare Sector Average

Performance Comparison

AFIB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AFIB	Acutus Medical, Inc.	―	―	―
RCEL	Avita Medical Ltd	15.63	11.77	304.92%
CLPT	Clearpoint Neuro, Inc.	8.48	-5.73	-40.32%
ECOR	Electrocore	5.25	-0.01	-0.19%
PAVM	Pavmed	1.63	-9.89	-85.85%
COCH	Envoy Medical, Inc. Class A	6.74	0.21	3.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: May 22, 2025

Acutus Medical AI Stock Analysis